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1Exercise and Manual therapy Arthritis Research trial (EMPART) for osteoarthritis of 
the hip: A Multicentre Randomised Controlled trial. 
ABSTRACT
Objective: To determine the effectiveness of exercise therapy (ET) compared to ET
 with adjunctive manual therapy (ET+MT) for people with hip osteoarthritis (OA). A
secondary aim was to identify if immediate commencement of ET or ET+MT was 
more beneficial than a 9 week waiting period for either intervention.   
Design: Assessor-blind randomised controlled trial with 9 and 18 week follow-ups.  
Setting: Four academic teaching hospitals, Dublin, Ireland.  
Participants: 131 patients with hip OA recruited from general practitioners,  
rheumatologists, orthopaedic surgeons, and other hospital consultants were 
randomised to one of three groups: ET (n=45), ET+MT (n=43) and wait-list 
control (n=43).  
Interventions: Participants in both ET and ET+ MT groups received up to 8  
treatments over 8 weeks. Control group participants were re-randomised into  
either ET or ET+MT group after 9 week follow-up. Their data were pooled  
with original treatment group data: ET (n=66) and ET+MT (n=65).  
Main Outcome Measures: The primary outcome was the WOMAC physical  
function (PF) subscale. Secondary outcomes included physical  
performance, pain, hip range of motion (HROM), anxiety/depression,  
quality of life, medication usage, patient-perceived change and patient 
satisfaction.
Results: There was no significant difference in WOMAC PF between ET  
(n=66) and ET+MT (n=65) groups at 9 weeks (mean diff 0.09 (95% CI -4.41,  
25.25)) or at 18 weeks (mean diff 0.42 (95% CI -3.98, 6.83)), or other  
outcomes, except ‘patient satisfaction with outcome’ which was higher in the  
ET+MT group (p=0.02). Improvements in WOMAC, HROM and patient- 
perceived change occurred in both treatment groups compared with the control  
group.  
Conclusion: Self-reported function, HROM and patient-perceived 
improvement occurred after an 8 week programme of ET for patients with hip OA
MT as an adjunct provided no further benefit, except for higher patient satisfaction. 
3LIST OF ABBREVIATIONS
ACR  American College of Rheumatology  
BMI     Body Mass Index  
CONSORT  Consolidated Standards of Reporting Trials   
EMPART  Exercise and Manual Physiotherapy Arthritis Research Trial  
ET   Exercise Therapy 
FABER   Flexion, abduction, external rotation 
HADS   Hospital Anxiety and Depression Scale  
HEP  Home Exercise Programme
ICC  Intraclass correlation co-efficient 
MCID   Minimal Clinically Important Difference
MT   Manual Therapy 
NRS  Numerical Rating Scale  
NSAID   Non–steroidal Anti-inflammatory Drugs 
OA   Osteoarthritis 
OR   Odds Ratio
PF   Physical Function 
PGA Patient Global Assessment
POPS  Physiotherapy Out-Patient Survey 
RCT  Randomised Controlled Trial 
ROM  Range of Motion 
SF-36   Short-Form-36 
STS  Sit-to-Stand
WOMAC   Western Ontario McMaster Universities Index
4Hip osteoarthritis (OA) is a painful and disabling condition which can  
impact on everyday activities and quality of life 1, 2. A lifetime prevalence
 of 25.3% has been reported 3 and this is associated with increasing age. 
Conservative treatments include exercise therapy (ET) and manual therapy 
(MT). 4, 5Although ET has demonstrated beneficial effects for hip OA in  
recommended core outcomes 6 of pain 7, 8 and patient perceived  
improvement (patient global assessment-(PGA) 9, 10 in the short and  
medium term, results for changes in physical function are conflicting. A 
number of  randomised controlled trials (RCTs), some of which have  
included participants with hip or knee OA, found functional benefits with  
exercise 9, 11, 12, but a meta-analysis, based on data from participants with  
hip OA only, found no effect on physical function 7. The small number of  
participants (n=204) and inter-study heterogeneity may have influenced 
this finding. Long-term (>6 months) follow-ups of exercise-based RCTs 
have found that post-treatment improvements in pain and function were not  
maintained  13-15, but it is unclear at what point benefits dissipate following  
treatment and long-term follow-up. There is therefore a need to identify the  
medium-term effects of physiotherapy for hip OA. 
MT, which is the use of hands-on techniques delivered to the joint or soft 
tissues to modulate pain and improve joint mobility 16,  is used for the 
treatment of pain and disability associated with hip OA 4, 5.  It can be 
administered as high velocity manipulative techniques or lower grade joint 
mobilisations 17, 18.  Although clinical guidelines recommend MT as an 
adjunctive therapy in the management of hip OA 19, the scientific evidence 
5supporting this recommendation is based on one RCT which compared 
manual therapy head to head with ET, rather than as an adjunct and found MT 
superior in pain, function and PGA outcomes 20. A more recent RCT found no 
difference in outcomes between ‘ targeted’ hip MT with exercise and ‘full kinetic 
chain’ MT with exercise delivered by chiropractors21. Neither of these trials 
included a control group.  The aim of this RCT was to determine if the addition of 
MT to an 8 week programme of ET for hip OA improved function and other 
clinical outcomes more than ET only at 9 and 18 weeks. A secondary aim was to 
ascertain if immediate commencement of treatment (ET or ET+MT) 
resulted in better outcomes compared with a 9 week waiting period for 
either intervention. 
METHODS 
Design 
The EMPART multicentre randomised controlled trial (RCT) was 
conducted in four academic teaching hospitals in an urban area in Ireland.  
The study was approved by each of the hospital’s research committees. An 
initial three group parallel arm trial (allocation ratio 1:1:1) was utilised, 
with a modified cross-over design, whereby control group participants  
were crossed over to one of two intervention arms after a 9 week period,  
thereby ensuring sufficient power to test the primary trial hypothesis. 
Details of the EMPART protocol are published elsewhere 22.
Participants 
6The principal investigator (HF) screened all patients for trial eligibility 
and enrolled participants following receipt of written informed consent.  
Participants referred from rheumatologists, orthopaedic surgeons, other  
hospital consultants and general practitioners were recruited from 
physiotherapy waiting lists. Waiting times for physiotherapy varied 
from 6 weeks to 6 months across the four trial sites. Participants were 
included if they had OA of the hip and were aged 40-80 years 
according to the American College of Rheumatology (ACR) criteria 23.
Exclusion criteria included previous hip arthroplasty, congenital or  
adolescent hip disease, clinical signs of lumbar spine disease,  
physiotherapy in the previous 6 months for hip symptoms, pregnancy,  
hip fracture, contraindications to exercise therapy 24, inflammatory 
arthritis, on waiting list for hip joint replacement within the next 7 
months, intra-articular hip corticosteroid injection in the previous 30  
days or insufficient English language to complete questionnaires.  
Randomisation 
Two computer generated randomisation lists were compiled by an 
independent statistician. The first list randomised participants into one 
of the three arms, namely ET, ET+MT or a waiting-list control group.  
The second list re-randomised control group participants into one of  
the two intervention groups (ET or ET+MT) after the 9 week follow- 
up assessment. Both lists were maintained by a member of the research 
team (TC) who was located offsite from the four trial centres and was 
7not involved in participant assessment or treatment. Simple 
randomisation was conducted, following email notification of patient  
recruitment by the principal investigator. Group allocation was  
communicated via email by the independent randomiser to the treating 
therapists in each treatment site 
Blinding 
A single assessor (HF), blinded to group allocation and measurement  
data from previous assessment points, carried out all outcome  
assessments. Patients were requested not to divulge information  
regarding allocated treatment. Disclosure of group allocation was recorded 
prospectively by the blinded assessor.  
Interventions 
The ET and ET+MT interventions were administered by senior grade  
or clinical specialist physiotherapists (n=23) in the four participating 
hospitals. Training in the two treatment protocols was provided by the 
principal investigator (HF) along with a comprehensive written manual 
to ensure a standardised approach to treatment across the trial centres. 
All therapists at all sites provided either ET or ET+MT interventions.  
All participants were treated according to the protocol which is  
detailed in Appendix 1.  
ET
8Participants attended six to eight individual 30 minute physiotherapy  
sessions over eight weeks, which included flexibility and strengthening  
exercises delivered using a semi-structured protocol. The protocol  
provided guidance on exercise prescription and progression, but could  
be tailored to individual patient physical assessment findings.  
Strengthening focused on low load exercise, commencing in non  
weight bearing positions and progressing to functional positions. The  
key target muscles were the gluteal muscles which are commonly 
atrophied in hip OA 25, 26. A daily home exercise programme (HEP) 
supplemented the clinic-based treatment.  Adherence to the home  
programme was measured using a self-report exercise diary. 
Participants were also encouraged to undertake aerobic exercise such 
as walking, cycling or swimming for at least 30 minutes, five days a 
week 27, and were given written and verbal information on the  
principles of aerobic conditioning such as pacing, gradually  
progressing intensity and time of exercise and incorporating exercise 
into daily life. 
ET+MT
Participants attended six to eight individual 45 minute physiotherapy  
sessions over an eight week period, which included 30 minutes of ET  
as previously described and up to 15 minutes of MT in line with  
current clinical practice at participating sites. A choice of non- 
manipulative MT techniques based on pain/ stiffness relationships 17, 18
9and movement restrictions of the affected hip were available, with no  
more than five MT techniques allowed during an individual session.  
Control Group  
Participants in the control group remained on the physiotherapy  
waiting list and completed a follow-up assessment with the blinded  
outcome assessor at 9 weeks, after which they were re-randomised into  
either ET or ET+MT group.  
All three groups received standardised written information on hip  
OA28. All non-consenting and excluded participants were treated as 
usual by the physiotherapy department in each trial centre. Participants 
were asked to avoid all other interventions for the duration of the RCT,  
apart from routine doctor care and analgesics. Participants with 
bilateral hip OA received clinic-based treatment for the more 
symptomatic hip only, but were provided with a home exercise  
programme for both hips.   
Outcomes 
Outcomes were chosen according to internationally recommended core 
outcomes for hip or knee OA 6. The primary outcome was self-reported  
physical function as measured by the Western Ontario and McMaster 
Universities Index physical function subscale for hip OA (WOMAC  
PF; Likert version) 29. This has moderate to high validity and reliability  
30 with lower scores indicating better functional status.  Secondary  
10
outcomes included observed physical function measured with the five  
times sit-to-stand test 31 and the 50-foot walk test 32 . Active hip range  
of motion (ROM) was measured using goniometry for flexion,  
abduction, medial rotation and Thomas test 33. These scores were 
combined to give an aggregate ROM score. FABER (combined  
flexion, abduction and lateral rotation) was measured separately using  
a measuring tape 34.  ROM and physical performance procedures  
demonstrated excellent test-retest reliability (ICC>0.90) in a subgroup  
of people with and without hip OA 35. Pain severity (with activity and 
at night) was measured using a numerical rating scale (NRS) and pain 
medication usage was quantified using the Medication Quantification  
Scale (MQS) 36. Other outcomes included general health status  
(Medical Outcomes Short-Form 36; SF-36) and psychological well- 
being (Hospital Anxiety and Depression Scale; HADS)37. Patient 
global assessment of change was assessed using a 7-point scale (very  
much worse to very much better) and the Physiotherapy Out-Patient 
survey (POPS) assessed patient satisfaction 38.
Sample Size 
The WOMAC PF subscale was used to estimate the sample size 
required. Using a previously ascertained minimal clinically important 
difference (MCID) of 5.4 (SD=11) on the WOMAC Likert scale 39,
with a significance level of 0.05 (2 tailed) and a power of 80%, 67  
patients were required per group, based on the final group allocation to  
ET or ET+MT. This was increased to 74 patients per group to allow for  
11
10% attrition at the 18 week follow-up, thus requiring a total sample of  
148 participants.  
Statistical Analysis
Analyses were conducted on an intention-to-treat (ITT) basis. Missing 
data were replaced using multivariate multiple imputation (Stata 
version 12, Statcorp, Texas, USA). Twenty imputed datasets were  
generated using a model whereby data were considered missing at 
random. Imputations were based on baseline demographic variables  
(age, gender, occupation and body mass index) and predictor variables  
such as symptom duration, baseline pain, physical function,  
psychological health and general health status). An overall significance 
level of p=0.05 was set. To address the primary study aim,  
comparisons were made between the ET and ET+MT groups at  
baseline, 9 and 18 weeks whereby participants in the control group  
were analysed according to the intervention received after the 9 week 
follow-up. Comparisons were made between the control group and the  
two treatment groups combined (ET and ET+MT) at baseline and 9  
weeks to address the secondary study aim. Linear regression modelling  
was used to examine between-group differences, with adjustment for  
baseline levels of the outcome. For the two group analysis, baseline  
WOMAC PF and aggregate ROM were included as co-variates due to
baseline differences.  Pain medication usage (MQS), aggregate ROM, 
sit-to-stand and WOMAC PF subscale were added as co-variates for 
the three group analysis due to baseline differences in these variables. 
12
Quantile regression was used for non-normally distributed outcomes.   
Patient global assessment ratings were dichotomised as improved (very 
much better, much better, somewhat better), no change and worse  
(very much worse, much worse and somewhat worse) and chi-squared  
analysis was used to test for differences between the groups.  
RESULTS 
Participants 
One hundred and thirty one patients were recruited across the four sites 
between May 2008 and February 2010. In the initial three group 
allocation, 43 patients were randomised each to the ET+MT and 
control groups, and 45 were randomised to the ET group. Figure 1 
shows participant flow through the trial. Eight patients (6.1%) 
withdrew from the trial at 9 weeks, four declined continuation, one had 
hip surgery, one developed cardiac symptoms, one could not be 
contacted by the researcher and one withdrew for family reasons. By 
18 weeks, a further 11 (8.4%) withdrew, six underwent hip surgery, 
one could not be contacted and four declined follow-up for personal 
reasons. This resulted in an overall drop-out rate of 14.5%. Table 1 
shows the baseline characteristics as determined by the two group (ET 
and ET+MT) allocation. Baseline characteristics for the three groups are 
shown in Table 2. 
Success of blinding 
Group assignment was disclosed to the outcome assessor by five  
13
participants, who were all in the control group. No treatment disclosure  
occurred in the two intervention groups.   
Outcomes 
Two group analysis (ET and ET+MT) 
At both 9 and 18 week time points, there was no significant difference  
between the ET and ET+MT groups for any outcomes (Table 3), with the  
exception of ‘patient satisfaction with outcome’ which was higher for  
the ET+MT group (Table 4).  
Three group analysis (Control vs. ET and ET+MT) 
At 9 weeks, analysis of data from the initial three group randomisation  
(Table 5) demonstrated significant improvements in the treatment 
groups compared to the control group in WOMAC PF, aggregate ROM  
and PGA. There was no significant difference between the control and 
two treatment groups in remaining outcomes.  
Treatment 
Twenty-two physiotherapists treated the patients in the EMPART 
study. The mean number of treatments for the ET group was 5.62  
(SD=1.99) and for the ET+MT group was 5.22 (SD=2.31). Fifty-two of  
the ET group (78.8%) and 50 (76.9%) of the ET+MT group received at  
least four of their planned treatments.  A total of 38 completed HEP  
diaries were available for analysis, 22 (40.7%) in the ET+MT group  
and 16 (28.1%) in the ET group. Mean duration of aerobic exercise per  
14
week undertaken by the ET group was 4.62 hours (+/- 0.91) and for the  
ET+MT group was 4.1 hours (+/- 0.6). Mean duration of the home  
exercise programme per week was 2.97 +/- 0.49 hours for the ET 
group and 3.57 +/- 0.31 hours for the ET+MT group.  
Discussion 
Primary Research Aim 
This assessor-blinded multicentre RCT assessed the effectiveness of 
the addition of MT to an 8-week ET programme for the treatment of 
hip OA. There was no significant difference between the ET and  
ET+MT groups in the majority of outcomes at 9 or 18 weeks, except  
‘patient satisfaction with outcome’. Due to the number of outcomes  
assessed in this study, this significant finding of satisfaction may have 
occurred by chance. Patients reported higher satisfaction with outcome for the  
ET+MT group, as in other trials of MT intervention for musculoskeletal  
disorders 40, 41. This coincides with the higher (although not statistically 
significant) proportion of participants who reported improvement with  
ET+MT compared with ET (Table 3). Satisfaction with other aspects of the 
physiotherapy interactions was comparable, possibly because both  
interventions were delivered by the same physiotherapists at the same 
locations.  
Comparison with other similar studies is limited as no known studies have  
evaluated ET with or without MT for hip OA, although a similar trial is 
underway in New Zealand 42. A recent study found no differences in ‘targeted’  
versus ‘full kinetic chain’ MT, both with additive ET for hip OA 21.  Hoeksma  
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et al, who compared MT head to head rather than as an adjunct to ET, found  
that MT alone had a superior effect on pain, function and  patient global  
assessment compared to ET 20. Reasons for these somewhat incongruous  
results may relate to the dosage of MT provided; Hoeksma et al used high  
velocity manipulations whereas lower grade mobilisation techniques were  
utilised 17, 18 in EMPART. The setting in which our RCT was located may  
affect external validity of these findings. The heterogeneity in clinical severity 
of the sample may have attenuated the treatment effect and the more severely 
affected patients may not be representative of those seen in a primary 
care setting. Although it is possible that treatment effects may differ 
for patients with varying OA severity, this trial was not powered to  
examine subgroup effects. Larger multicentre studies are required to  
identify if effects of ET and MT differ depending on OA severity.  
Secondary Aim 
Both groups improved in self-reported physical function, aggregate  
ROM and patient perceived improvement relative to the control group  
in the short-term (9 weeks). This was a similar finding to other RCTs 
which evaluated exercise for hip OA such as graded behavioural  
exercise 10, tai chi and hydrotherapy 43, group-based strengthening 12
and individualised exercise 9, 20. However, some of these studies  
included people with hip or knee OA 9, 10, 43, so the evidence regarding  
the optimal exercise approach for hip OA alone has yet to be identified.  A  
moderate treatment effect on pain for hip OA has been ascertained in 
two meta-analyses 7, 8 with no significant effect on function, based on  
five RCTs 7. The original RCTs which demonstrated a benefit of ET 
16
included data from trials which included participants with hip or knee  
OA 9, 11, 43 whereas the meta-analysis extracted hip OA data only. This 
highlights the limitations of including people with hip or knee OA in  
the same trial and exposing them to similar interventions, as important 
differential effects may be missed. 
The minimal clinically important difference (MCID) for WOMAC PF 
has previously been determined as 5.4 39. In our trial, the mean improvement  
at 9 weeks was 6.25 for ET+MT and 4.21 for ET (Table 5), which suggests  
that the clinical significance of the improvement in EMPART is questionable. 
Deterioration in WOMAC physical function (Table 5) in the control  
group over such a short timeframe was a surprising outcome. The  
unblinded status of participants may have influenced these results,  
introducing cognitive measurement bias which can occur with  
subjective patient-reported outcomes, where control group participants  
report negative outcomes due to disappointment at not receiving the 
target intervention 44. It may also relate to the inclusion of patients with 
severe symptoms, compared with other studies which included those  
with mild/moderate symptoms 9, 12. The participants in this trial were 
recruited in a hospital setting where the majority of patients were 
initially referred from primary care physicians to rheumatology and  
orthopaedic specialists, and onward to physiotherapy. This care  
pathway increases the waiting time for patients to receive rehabilitation 
from the time of onset of symptoms.   
The influence of the therapist –patient interaction cannot be outruled as  
17
a reason for improvements in the two intervention groups, compared  
with the control group. It has been shown that interventions which  
include a specific therapeutic relationship may contribute to the 
treatment effect 45.
In EMPART, although self-report physical function improved as a  
result of both ET and ET+MT interventions, there was no change in  
physical performance tests. The 50 foot walk may have been too short  
in distance to detect change as longer walk tests have been shown to be 
more responsive to change in people with OA 46 and assessment of a 
range of physical performance tasks may be preferable 9.   
Neither intervention in this RCT had a significant impact on 
psychological status or general health even though reduced quality of  
life and depression prevail in OA 47. Similar findings occurred in other  
RCTs of ET for lower limb OA 9, 10, 43, and suggests that exercise on its  
own does not impact on the wider psychosocial manifestations of OA.  
Although the exercise programme in this trial provided information on  
self-management principles, it did not use behavioural or cognitive  
approaches to empower participants. Lack of significant change may 
also have been limited by the outcomes used (SF-36 and HADS), both  
of which have previously demonstrated lower responsiveness to  
change than OA-specific measures 48, 49.
This study utilised a rigorous methodology, such as blinding of the  
outcome assessor, independent central randomisation, allocation  
18
concealment, validated outcome measures, highly reliable physical 
measures and intention-to-treat analysis using multiple imputation.  
Simple randomisation was used over block randomisation as the 
recruitment locations (acute teaching hospitals in an urban area) were 
comparable. The principal investigator who screened all participants  
was an experienced musculoskeletal physiotherapist and was able to 
effectively and systematically screen patients for suitability and ensure  
that patients with primary lumbar spine pathology were excluded.  
Study Limitations 
A type II error may have occurred in relation to the two group analysis  
due to failure to reach the target sample size. Post-hoc power analysis 
based on the 131 recruited patients and accounting for drop-out rate 
 provided a power of 73.8%, at a significance level of 0.05, resulting in  
a loss of power of less than 7%. Attrition rate at the 18 week follow-up  
was higher than the a-priori estimated rate of 10%. No long-term 
follow up data are presented, thus limiting the interpretation of the  
results. The lack of blinding of both patients and physiotherapists can  
also be considered as a limitation, although it is well recognised that  
blinding is virtually impossible to achieve in non-pharmacological 
trials 50.  The low return of the completed HEP diaries is also worth  
noting but may be related to the study design. Participants were asked  
to return diaries to the treating therapists, to maintain assessor 
blinding. Due to the high number of treating therapists, this proved difficult to 
implement successfully.    
19
CONCLUSIONS
This RCT demonstrated that an 8 week programme of ET, with and without  
adjunctive MT for people with hip OA, showed similar improvements in self
report function, ROM and patient global assessment at 9 weeks which were  
maintained at 18 weeks.  However, the clinical meaningfulness of these  
changes is questionable. Patient satisfaction was higher for those who received 
adjunctive MT. These findings highlight the benefit of physiotherapy-based 
exercise for those with hip OA, but no additive benefit from the use of  
additional manual therapy. More research is required to identify the optimal  
components of rehabilitation required to target the multifaceted elements of 
hip OA.  
Figure legends
Fig 1: Flow of participants through the trial
Fig 2: CONSORT Checklist
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*Analysed at 18 weeks (n=43) 
ET+MT (n=22); ET (n=21) 
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(n=5) 
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Unable to contact 
(n=1) 
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(n=1) 
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Surgery (n=1) 
Lost to follow-up (n=0) 
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*Analysed at 27 weeks (n=43) 
ET+MT (n=22); ET (n=21) 
 
Figure 1: Flow of participants through the trial. 
*missing data were imputed using multiple imputation methods  
Table 1: Baseline characteristics for the ET and ET+MT groups  
                                                                                  ET (n=66)                           ET+MT (n=65)                                                                                  
  Number (% within group ) Number (% within group ) 
Gender      Female 44 (66.7%) 40 (61.5%) 
Body Mass Index 
(kg/m2) 
Normal 
Overweight/Obese 
15 (23.7%) 
51 (76.3%) 
18 (27.7%) 
47 (72.3%) 
Referral Source  
    
Orthopaedics 
Rheumatology 
GP  
Other Consultants 
20 (30.3 %) 
26 (39.4 %) 
15 (22.7 %) 
  5 (7.5%) 
17 (26.2 %) 
37 (56.9 %) 
  7 (10.8 %) 
  4 (6.1%) 
Occupation  
 
Retired 
Homemaker 
Paid Employment 
Other  
24 (36.4 %) 
22 (33.3 %) 
16 (24.2 %) 
 4 (6%) 
16 (24.6%) 
20 (30.8%) 
23 (35.3%) 
6 (9.25%)  
Pain Medications No Medication 
Analgesics 
NSAIDS 
21 (31.8%) 
37 (56.1%) 
24 (36.4%) 
17 (26.2%) 
39 (60%) 
21 (32.3%) 
Hip Affected 
     
One  
Both 
55 (73.3%) 
11 (16.7 %) 
45 (69.2%) 
20 (30.8 %) 
  Mean (SD) Mean (SD) 
Age  (years) 62.44  ( 9.09) 61.43 (10.76) 
Symptom Duration  (months) 33.21 (37.77) 36.43 (51.75) 
Comorbidities  (number) 1.97 (1.36) 2.38 (1.45) 
WOMAC Physical 
Function 
 33.48  (14.67) 35.57 (13.57) 
 
HADS Anxiety  6.10 (3.86) 
 
6.17 (4.27) 
 
HADS Depression  4.92 (3.40) 
 
4.50 (3.01) 
 
SF-36 PCS  36.17 (9.42) 
 
34.31 (8.95) 
 
SF-36 MCS  50.99 (12.24) 
 
50.65 (11.02) 
 
Aggregate ROM (degrees) 119.36 (27.62) 125.18 (24.36) 
 
FABER ROM (cm)  30.99 (7.15) 
 
32.09 (6.57) 
 
Sit-to-Stand (seconds) 
 
 
13.60 (6.18) 
 
14.72 (9.45) 
 
50 foot walk test (seconds) 
 
14.14 (7.20) 
 
14.44 (5.81) 
 Pain with Activity 5.64 (2.80) 
 
5.88 (2.28) 
 
Pain at Night 5.12 (3.27) 
 
4.59 (3.34) 
 
Pain medication usage (MQS) 
 
6.03 (5.64) 
 
5.84 (4.94) 
 
Cm=centimetres; ET=Exercise Therapy; ET+MT =Exercise therapy and Manual therapy; FABER=Flexion, 
Abduction, External Rotation; GP= General practitioner; IRQ=Interquartile range; MCS=Mental Component 
Summary; MQS=Medication Quantification Scale; NSAIDS= Non-Steroidal Anti-Inflammatory Drugs; 
PCS=Physical Component Summary ROM=range of motion; SD=Standard Deviation; SF-36= Short-Form 36.

Table 2: Baseline characteristics for the ET, ET+MT and control groups 
ET=Exercise Therapy; ET+MT =Exercise therapy and Manual therapy; FABER=Flexion, abduction, external rotation;
IRQ=Interquartile range; ROM=range of motion; SD=Standard Deviation; SF-36= Short-form 36; PCS=Physical 
Component Summary; MCS=Mental Component Summary; cm=centimetres; q= degrees
ET
(n= 45) 
ET+MT 
(n= 43) 
Control
(n= 43) 
Number  (% within 
each group)
Number  (% within each 
group)
Number  (% within each 
group)
Gender Male
Female
11 (24.4%)
34 (74.5%)
16 (37.2%)
27 (62.8%)
20 (46.5%)
23 (53.5%)
Body Mass Index 
(kg/m2)
Normal 
Overweight /Obese 
13 (28.9%)
32 (71.1%)
9 (20.9%)
34 (79.1%)
7 (16.3%)
36 (84.7%)
Pain Medications† No Medications
Analgesics
NSAIDs 
14 (36.8%)
24 (53.3%)
14 (31.1%)
10  (26.3%)
27 (62.8%)
16 (37.2%)
14 (36.8%)
25 (58.1%)
15 (34.9%)
Referral Source Orthopaedics
Rheumatology 
GP
Other  Consultants
14 (31.1%)
17 (37.8%)
12 (26.7%)
2 (4.4%)
11 (25.6%)
27 (62.8%)
4 (9.3%)
3 (6.6%)
12 (27.9%)
21 (48.8%)
5 (14.7%)
3 (2.7%)
Occupation Retired 
Homemaker
Paid Employment
Other 
16 (35.6%)
11 (22.4%)
16 (35.6%)
2 (4.5%) 
16 (35.6%)
18 (41.9%)
13 (30.2%)
4 (9.3%)
15 (34.9%)
13 (30.2%)
11 (25.6%)
4 (9.3%)
Hip Affected Left 
Right 
Both
13 (28.95)
23 (51.1%)
9 (20%)
8 (18.6%)
20 (46.5%)
15 (34.9%)
9 (23.35)
26 (60.55)
7 (16.35)
Use of Walking Aids None
Stick for long walk
Stick most of time
38 (84.4%)
4 (8.9%)
3 (6.7%)
36 (83.7%)
2 (4.7%)
5 (11.6%)
39 (90.6%)
2  (4.7%)
2 (4.7%)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 61.76 (9.72) 64.83 (9.82) 60.81 (9.73)
Symptom Duration (months) 33(41.56) 37.16  (59.8) 33.3 (30.04)
Co-morbidities 2 (1.26) 2.6 (1.48) 1.86 (1.36)
WOMAC Function 32.29 (12.21) 35.56 (13.39) 32.91 (14.88)
HADS Anxiety 5.80 (3.35) 6.42 (4.68) 5.07 (3.29)
HADS Depression 4.58 (2.95) 4.28 (3.54) 4.37 (2.85)
SF-36 PCS 36.51 (9.87) 35.27 (8.75) 36.60 (9.11)
SF-36 MCS 52.78 (10.75) 50.56 (11.02) 52.82 (11.48)
Aggregate ROM (°) 122.65 (21.62) 121.56 (26.24) 124.87 (24.47)
FABER ROM (cm) 31.36 (5.68) 33.42 (5.84) 29.33 (7.41)
Sit-to-Stand (seconds) 13.18 (4.71) 15.88 (11.20) 14.15 (6.23)
50 foot walk test (seconds) 13.72 (4.37) 15.18 (6.44) 13.52 (5.69)
Median (IRQ) Median (IRQ) Median (IRQ)
Pain with Activity 6 (4) 6 (3) 5 (4)
Pain at Night 5 (5) 5 (6) 4 (7)
Pain at Rest 3 (5) 4 (5) 3 (5)
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Table 4: Patient satisfaction and global assessment of change outcomes for ET 
and ET+MT groups              
* Chi-squared analysis; † Mann-Whitney U test
ET=Exercise Therapy; ET+MT=Exercise therapy and Manual Therapy; CI=Confidence interval;
IRQ=Interquartile range; OR=Odd’s Ratio.
Physiotherapy Outpatient 
Survey  (POPS) at 18 
weeks 
ET+MT
Median (IQR)
(n=65)
ET
Median (IQR)
(n=66)
Median Difference 
between groups 
(95%CI)
p-value
(between
group)†
Expectations (0-5) 3.40 (1.05) 3.60 (1.00) -0.2 (-0.42,0.40) 0.44
Communication (0-5) 4.5 (0.83) 4.5 (0.83) 0 (-0.34,0.35) 0.27 
Therapist (0-5) 4.67 (0.83) 4.31 (0.67) 00.36 (-0.50,0.01) 0.12
Organisation (0-5) 4.29 (0.93) 4.14 (0.71) 0.15 (-0.43,0.16) 0.50
Outcome (0-5) 3.20 (1.20) 2.80 (1.00) 0.40 (00.60,0.00) 0.02
Satisfaction (0-5) 4.17 (0.59) 4.25 (0.67) -0.07 (-0.16,0.16) 1.00
Overall  (0-5) 4.01 (0.52) 3.97 (0.56) -0.04 (0.32,0.06) 0.17
Patient Global Assessment Number (%) 
improved
Number (%) 
improved
OR (95% CI) p-value*
(between
group)
9 weeks 45 (69.7%) 40 (60.6%) 1.46 (0.72, 2.98) 0.73
18 weeks 33 (50.8%) 28 (42.4%) 1.39 (0.70, 2.76) 0.87
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